Reporter on the 14th from the State Council joint prevention and control mechanism of scientific research group was informed that China’s two new coronavirus inactivated vaccine to obtain the State Drug Administration of the first and second phase of the combined clinical trial license, to become the first batch of new coronavirus inactivated vaccine to obtain clinical research approvals. These two inactivated vaccines were developed by Wuhan Biological Products Research Institute of China Biological Corporation of Sinopharm Group and Beijing Kexing Zhongwei Biotechnology Co. Inactivated vaccine is a kind of vaccine that kills the pathogenic microorganisms but still maintains its immunogenicity, and it has the advantages of mature production process, controllable quality standard and wide protection range. China’s vaccine emergency research is currently in accordance with the inactivated vaccine, recombinant protein vaccine, adenovirus vector vaccine, live attenuated influenza virus vector vaccine, nucleic acid vaccine five technical routes to promote. Previously, the adenovirus vector vaccine of the Military Medical Research Institute of the Military Academy of Sciences has been approved to carry out clinical trials. Source: Beijing Daily